Using real-world evidence to complement evidence from randomized controlled trials on oral anticoagulants for stroke prevention.

IF 15.8 1区医学 Q1 Medicine

PLoS Medicine Pub Date : 2024-08-29 eCollection Date: 2024-08-01 DOI:10.1371/journal.pmed.1004449

Mark J R Smeets, Suzanne C Cannegieter

引用次数: 0

Abstract

Mark J. R. Smeets and Suzanne C. Cannegieter discuss the use of real world data to complement data generated by clinical trials of systemic anticoagulants.

查看原文本刊更多论文

利用真实世界的证据来补充口服抗凝剂预防中风随机对照试验的证据。

Mark J. R. Smeets 和 Suzanne C. Cannegieter 讨论了如何利用真实世界的数据来补充全身性抗凝剂临床试验所产生的数据。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

PLoS Medicine MEDICINE, GENERAL & INTERNAL-

CiteScore

17.60

自引率

0.60%

发文量

227

审稿时长

4-8 weeks

期刊介绍： PLOS Medicine is a prominent platform for discussing and researching global health challenges. The journal covers a wide range of topics, including biomedical, environmental, social, and political factors affecting health. It prioritizes articles that contribute to clinical practice, health policy, or a better understanding of pathophysiology, ultimately aiming to improve health outcomes across different settings. The journal is unwavering in its commitment to uphold the highest ethical standards in medical publishing. This includes actively managing and disclosing any conflicts of interest related to reporting, reviewing, and publishing. PLOS Medicine promotes transparency in the entire review and publication process. The journal also encourages data sharing and encourages the reuse of published work. Additionally, authors retain copyright for their work, and the publication is made accessible through Open Access with no restrictions on availability and dissemination. PLOS Medicine takes measures to avoid conflicts of interest associated with advertising drugs and medical devices or engaging in the exclusive sale of reprints.